The mainte- nance dose should be 81 mg daily in patients treated with ticagrelor and 81 mg to 325 mg daily in all other (Level of Evidence: A) 2. In addition to aspirin, a P2Y12 inhibitor (either clopi- dogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia- guided strategy. Options include: Clopidogrel: 75 mg daily289,296 (Level of Evidence: B) or Ticagrelor : 90 mg twice daily293,294 (Level of Evidence: B) 3. In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least 12 months.330 Options include: Clopidogrel: 75 mg daily296,331 (Level of Evidence: B) or Prasugrel#: 10 mg daily302 (Level of Evidence: B) or Ticagrelor : 90 mg twice daily293 (Level of Evi dence: B) Class IIa 1. It is reasonable to use an aspirin maintenance dose of 81 mg per day in preference to higher maintenance The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.290 #Patients should receive a loading dose of prasugrel, provided they were not pretreated with another P2Y12 receptor inhibitor. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e377 Table 10. 